| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 10 | 2023 | 1384 | 1.930 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2020 | 298 | 1.160 |
Why?
|
| Apoptosis Regulatory Proteins | 11 | 2021 | 621 | 1.150 |
Why?
|
| Phosphoproteins | 8 | 2014 | 1230 | 1.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 8 | 2014 | 1295 | 0.970 |
Why?
|
| Cell Proliferation | 16 | 2023 | 7308 | 0.760 |
Why?
|
| Benzimidazoles | 3 | 2015 | 441 | 0.740 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2020 | 278 | 0.670 |
Why?
|
| Neoplastic Stem Cells | 6 | 2020 | 1469 | 0.650 |
Why?
|
| Ovarian Neoplasms | 12 | 2020 | 4797 | 0.630 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2014 | 473 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2020 | 3934 | 0.600 |
Why?
|
| Cytoplasm | 4 | 2011 | 719 | 0.550 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 1004 | 0.530 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2011 | 183 | 0.520 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2015 | 45 | 0.520 |
Why?
|
| Adenovirus E1A Proteins | 6 | 2007 | 165 | 0.510 |
Why?
|
| Apoptosis | 16 | 2020 | 7842 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 9101 | 0.460 |
Why?
|
| Receptor, ErbB-2 | 10 | 2015 | 2649 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2019 | 4964 | 0.390 |
Why?
|
| Cell Line, Tumor | 23 | 2021 | 14888 | 0.380 |
Why?
|
| Antineoplastic Agents | 12 | 2020 | 14651 | 0.350 |
Why?
|
| Mice, Nude | 8 | 2023 | 4360 | 0.350 |
Why?
|
| Breast Neoplasms | 14 | 2017 | 16252 | 0.340 |
Why?
|
| Quinazolines | 6 | 2014 | 953 | 0.330 |
Why?
|
| Mice | 17 | 2023 | 36058 | 0.280 |
Why?
|
| Autophagy | 2 | 2014 | 921 | 0.280 |
Why?
|
| Animals | 21 | 2023 | 62826 | 0.270 |
Why?
|
| Genetic Therapy | 5 | 2007 | 1739 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 1720 | 0.260 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2005 | 20 | 0.260 |
Why?
|
| Thionucleotides | 1 | 2005 | 67 | 0.260 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 12016 | 0.250 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 162 | 0.250 |
Why?
|
| ErbB Receptors | 6 | 2014 | 2383 | 0.240 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 2219 | 0.230 |
Why?
|
| Leucine Zippers | 1 | 2023 | 41 | 0.220 |
Why?
|
| Indoles | 2 | 2020 | 1034 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10758 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 1237 | 0.210 |
Why?
|
| Cell Movement | 2 | 2021 | 2504 | 0.210 |
Why?
|
| Blotting, Western | 6 | 2014 | 3646 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 5804 | 0.200 |
Why?
|
| Dipeptides | 1 | 2020 | 97 | 0.180 |
Why?
|
| Female | 32 | 2020 | 149291 | 0.170 |
Why?
|
| Humans | 39 | 2023 | 272039 | 0.170 |
Why?
|
| Mice, SCID | 3 | 2020 | 1851 | 0.170 |
Why?
|
| Interleukin-8 | 1 | 2021 | 531 | 0.160 |
Why?
|
| Caspases | 3 | 2010 | 687 | 0.160 |
Why?
|
| Lactones | 1 | 2019 | 93 | 0.160 |
Why?
|
| Transfection | 6 | 2020 | 3166 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2011 | 253 | 0.150 |
Why?
|
| Enzyme Activation | 4 | 2019 | 1831 | 0.150 |
Why?
|
| Phosphorylation | 8 | 2019 | 4983 | 0.150 |
Why?
|
| Acetanilides | 1 | 2017 | 17 | 0.140 |
Why?
|
| Deoxycytidine | 2 | 2020 | 1378 | 0.140 |
Why?
|
| Quinoxalines | 1 | 2017 | 98 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2016 | 143 | 0.140 |
Why?
|
| Gangliosides | 1 | 2017 | 97 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 304 | 0.130 |
Why?
|
| Aurora Kinase B | 1 | 2015 | 68 | 0.130 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 289 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 220 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2019 | 272 | 0.120 |
Why?
|
| Genetic Vectors | 2 | 2014 | 1887 | 0.120 |
Why?
|
| Drug Design | 1 | 2017 | 378 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2011 | 398 | 0.120 |
Why?
|
| Cisplatin | 2 | 2020 | 2500 | 0.120 |
Why?
|
| Prognosis | 5 | 2020 | 22543 | 0.120 |
Why?
|
| Aurora Kinase A | 1 | 2015 | 212 | 0.120 |
Why?
|
| Receptors, Prolactin | 1 | 2014 | 29 | 0.120 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 250 | 0.120 |
Why?
|
| Trastuzumab | 2 | 2015 | 736 | 0.120 |
Why?
|
| Prolactin | 1 | 2014 | 174 | 0.110 |
Why?
|
| Indazoles | 1 | 2015 | 310 | 0.110 |
Why?
|
| Carcinogenesis | 2 | 2017 | 1037 | 0.110 |
Why?
|
| Stathmin | 1 | 2013 | 31 | 0.110 |
Why?
|
| Integrin alpha6 | 1 | 2013 | 19 | 0.110 |
Why?
|
| G1 Phase | 2 | 2011 | 306 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 1966 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2015 | 5422 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2011 | 300 | 0.110 |
Why?
|
| Transgenes | 1 | 2014 | 589 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 1209 | 0.100 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2011 | 46 | 0.100 |
Why?
|
| RNA Interference | 2 | 2017 | 1397 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 449 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 5105 | 0.090 |
Why?
|
| Imidazoles | 1 | 2017 | 1061 | 0.090 |
Why?
|
| Neoplasms | 2 | 2017 | 15914 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 254 | 0.090 |
Why?
|
| Gene Expression | 3 | 2015 | 3690 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2020 | 12228 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 772 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2014 | 2035 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 557 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 2470 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2399 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2010 | 457 | 0.080 |
Why?
|
| Benzamides | 1 | 2014 | 1882 | 0.080 |
Why?
|
| Astrocytoma | 1 | 2010 | 336 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 505 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 889 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2010 | 1041 | 0.070 |
Why?
|
| Pyridines | 1 | 2014 | 1312 | 0.070 |
Why?
|
| Survival Rate | 1 | 2020 | 12547 | 0.070 |
Why?
|
| Piperazines | 1 | 2015 | 2147 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 202 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2007 | 2457 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2005 | 117 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10369 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2005 | 188 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4350 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 498 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 31071 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 257 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2010 | 2150 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2472 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2007 | 2106 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 5112 | 0.050 |
Why?
|
| Disease Progression | 1 | 2014 | 6909 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 782 | 0.050 |
Why?
|
| Aged | 6 | 2012 | 73500 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2007 | 2085 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 1547 | 0.050 |
Why?
|
| Carcinoma | 1 | 2014 | 2623 | 0.050 |
Why?
|
| Adult | 6 | 2012 | 81993 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 1014 | 0.050 |
Why?
|
| Paclitaxel | 3 | 2013 | 2102 | 0.050 |
Why?
|
| Middle Aged | 6 | 2012 | 90457 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 58 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 16628 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2006 | 1740 | 0.040 |
Why?
|
| DNA | 2 | 2006 | 3089 | 0.040 |
Why?
|
| Guanidine | 1 | 2019 | 14 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 71 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2013 | 3078 | 0.040 |
Why?
|
| Cell Death | 2 | 2014 | 689 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1472 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2019 | 582 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2007 | 1545 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 212 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5330 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3417 | 0.040 |
Why?
|
| Sialyltransferases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2019 | 640 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1930 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2007 | 3671 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 437 | 0.030 |
Why?
|
| Heterografts | 1 | 2019 | 745 | 0.030 |
Why?
|
| Mutation | 2 | 2014 | 15954 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 162 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 248 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5841 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 910 | 0.030 |
Why?
|
| Binding Sites | 1 | 2019 | 2298 | 0.030 |
Why?
|
| Ki-67 Antigen | 2 | 2010 | 685 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 109 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2014 | 89 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 6517 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 7830 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2319 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2014 | 235 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 706 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 3262 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 217 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 4994 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2012 | 33 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 419 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 1575 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2012 | 39828 | 0.020 |
Why?
|
| Time Factors | 1 | 2006 | 13135 | 0.020 |
Why?
|
| Microtubules | 1 | 2013 | 330 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 1501 | 0.020 |
Why?
|
| Telomerase | 1 | 2014 | 543 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 5604 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 681 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 340 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1364 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 507 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 621 | 0.020 |
Why?
|
| Liposomes | 2 | 2002 | 711 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1212 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 995 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2007 | 125 | 0.020 |
Why?
|
| Dinoprost | 1 | 2007 | 37 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 4138 | 0.020 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2012 | 531 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 2711 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2496 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 203 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 360 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2007 | 196 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 569 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1649 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 358 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1409 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 593 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2006 | 259 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2007 | 222 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 570 | 0.020 |
Why?
|
| Protein Transport | 1 | 2007 | 739 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2268 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 725 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2007 | 829 | 0.010 |
Why?
|
| Plasmids | 1 | 2006 | 953 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2011 | 3146 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2974 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5187 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3854 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1146 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 2912 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 7239 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 58 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7481 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 287 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 228 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 5502 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 3075 | 0.010 |
Why?
|
| Thorax | 1 | 2001 | 231 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6783 | 0.010 |
Why?
|
| Survival | 1 | 2000 | 184 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4398 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 10258 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 191 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 481 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 895 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 681 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 1086 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 9318 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 3395 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 15273 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3651 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 3299 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4496 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 7963 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 33913 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 2830 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 22173 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 9050 | 0.010 |
Why?
|
| Male | 1 | 2010 | 129081 | 0.000 |
Why?
|